{
    "organizations": [],
    "uuid": "940c88c5019da30df7a179f5ba4bf94811a0783c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/ionis-astrazeneca/ionis-to-get-up-to-300-mln-from-licensing-deal-with-astrazeneca-idUSL3N1RM39M",
    "ord_in_thread": 0,
    "title": "Ionis to get up to $300 mln from licensing deal with AstraZeneca",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.\nAstraZeneca will pay Ionis a $30 million license fee based on a certain milestone in development. (Reporting by Mrinalini Krothapalli; Editing by Sriraj Kalluvila)\n ",
    "published": "2018-04-09T19:29:00.000+03:00",
    "crawled": "2018-04-10T13:04:48.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "ionis",
        "pharmaceutical",
        "said",
        "monday",
        "signed",
        "licensing",
        "deal",
        "fatty",
        "liver",
        "disease",
        "treatment",
        "astrazeneca",
        "plc",
        "could",
        "land",
        "company",
        "million",
        "milestone",
        "payment",
        "royalty",
        "astrazeneca",
        "pay",
        "ionis",
        "million",
        "license",
        "fee",
        "based",
        "certain",
        "milestone",
        "development",
        "reporting",
        "mrinalini",
        "krothapalli",
        "editing",
        "sriraj",
        "kalluvila"
    ]
}